Fully-Human IgG Isotype Control mAbs
Perfect negative controls for your drug discovery research.
항체 의약품 개발과정에서 control로 사용하는 humanized antibody 등을 공급하는 회사입니다. 일반적으로
사람에게서 분리한 IgG 등을 control로 하는 경우가 있습니다만, mouse 등에 투여하면 mouse 조직과 반응하는
경우가 있습니다. Eureka Therapeutics, Inc.의 제품은 사람, mouse와 교차하지 않아서 정확한 실험결과를 얻을 수
Distinguishing antibody target-specific effects from backbone effects is crucial to the drug discovery
process. Nonspecific effects initiated by the antibody Fc backbone complicate the interpretation of in vitro
and preclinical results for antibody drug candidates (fully-human, humanized, or chimeric).
Eureka offers a collection of fully-human monoclonal antibodies for use as negative controls in vitro and for
- Specificity : Binds specifically to a hapten that does not exist in mammalian cells
- Source : Produced recombinantly, in CHO cells (serum-free culture)
- Purification : > 95% pure (by SDS-PAGE); Purified by Protein A affinity chromatography
- Formulation : Preclinical-grade: 1mg/ml, (PBS)
- Applications : ELISA, immunoblotting, FACS, IHC, preclinical studies
Figure 1 : Demonstration of the use of ET901 as a negative control for immunoprecipitation of ErbB2.
Precipitant samples in lanes 1-4 are as follows: MW, Herceptin (humanized anti-ErbB2 IgG1 molecule),
ET901, A/G beads only.
Figure 2 : Validation of negative binding against human cells: a) FACS analysis of ET901 on live SW900 cells
and b) FACS analysis of ET901 on permeabilized SW900 cells at a concentration of 1 ug/ml for all antibodies.
Figure 3 : Immunohistostaining of mouse kidney cells: a) negative staining by ET901 and b) positive staining
of kidney proximal tubules by positive antibody.
Figure 4 : Progression of weight for each experimental group throughout toxicity study. Weight of mice was
measured 2 times per week for three weeks.
Figure 5 : FACS analysis validation of ET903 negative binding on MDA-MB-231 human breast cancer cells.